pancreatic cancer
Conditions
Interventions
experimental group:neurolytic splanchnic nerve block (ethanol neurolysis)
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily endorse informed consent; 2. Male or female and 18 years of age or older; 3. Any kinds of diagnostic methods for definite diagnosis of advanced pancreatic cancer (stage III or IV); 4. Patients who claim that he or she will not undergo any kinds of radiotherapy and chemotherapy on tumor; 5. Pancreatic cancer-related pain and VAS?4; 6. Subjects who can be able to follow the drug dose and the follow-up plan; 7. Subjects who can objectively describe the symptoms, can take the initiative to cooperate, without any mental illness.
Exclusion criteria
Exclusion criteria: Subjects complying with any of the following exclusion criteria are not eligible to participate in this study: 1. Patients who have any objections to this trial; 2. Serious organ damage, such as CHF (congestive heart-failure), patients with clinical symptoms of coronary artery disease and arrhythmia uncontrollable by existing medicines, etc.; 3. Past history of severe cerebrovascular disease; 4. Patients with allergic diseases, allergic constitution, drug allergic history (oxycodoneal,morphine,alcohol,local anesthetics); 5. Patients with intracranial metastases and consciousness disorders; 6. Intervertebral disc infection, severe systemic infection; 7. Coagulation dysfunction; 8.Patients with psychiatric disease affecting assessments; 9. Patients in other clinical research at the same time; 10. The patients that researchers do not consider fit for the trial; 11. Patients who had received previous Neurolytic Celiac Plexus Block or other neurolytic blocks that could affect pancreatic cancer-related pain or had implanted epidural or intrathecal analgesic therapy; 12. Patients receiving radical/curative pancreatic cancer surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analogue Scale/Score(VAS); | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;opioid consumption;short form 36 questionnaire; | — |
Countries
China
Contacts
Public ContactSong Tao
The First Affiliated Hospital of China Medical University
Outcome results
None listed